« Canadian Marketing Rights to Xyrem®, Signed By Jazz Pharmaceuticals With Valeant Pharmaceuticals | Main | Lux Biosciences Received USFDA Orphan Drug Designation for Ophthalmic Indications of ISA247 »

Jan16
Long Term Dose-dependent Use of Genzyme Corp.’s Cerezyme® (imiglucerase for injection), Improve Bone Mineral Density in Type 1 Gaucher Disease Patients

The long term dose-dependent use of Genzyme Corporation (Nasdaq: GENZ)’s Cerezyme® (imiglucerase for injection) has been found to significantly improve bone mineral density in patients with Type 1 Gaucher disease.

Gaucher disease is a condition wherein patients suffering from it are at an increased risk of developing bone complications, including including osteopenia, osteoporosis and fractures.

Cerezyme.jpgAn enzyme replacement therapy, Cerezyme® is the standard care of treatment for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly.

The largest-ever retrospective analysis of more than 500 patients participating in the International Collaborative Gaucher Group (ICGG) Gaucher Registry have evaluated the effect of long term Cerezyme® use on bone mineral density.

The analysis found that patients receiving Cerezyme experienced a significant increase in bone mineral density over time when compared with patients who were not treated.

Furthermore, the improvements in bone mineral density were found to be dose-dependent, with those patients receiving higher doses of Cerezyme achieving greater increases in bone mineral density.

On average, the patients receiving Cerezyme at 60 units per kilogram biweekly achieved scores that approached those in the general population, whereas the untreated patients experienced no improvement or declining bone mineral density over the same period.

Such were the findings reported in a study published in the January issue of the Journal of Bone and Mineral Research.

Find more details from the Genzyme press release.

[Photo Credit: www.samohfarmachem.co.kr]


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Canadian Marketing Rights to Xyrem®, Signed By Jazz Pharmaceuticals With Valeant Pharmaceuticals | Main | Lux Biosciences Received USFDA Orphan Drug Designation for Ophthalmic Indications of ISA247 »

Advertise

Watch the Digital Health Revolution


Related Resources

recent comments

    sponsored ads



    subscribe


    Prefer Email?
    Subscribe below-

    Enter your Email:


    Powered by FeedBlitz What's this?

    Current News

    Support This Blog

    blogroll


    top blogs

    business social media

    Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

    BIZZlogos - Add your logo - free link to your site
    BIZZphotos - Add photos of your products and people
    BIZZprofiles - Submit your profile and build your online visibility
    BIZZspotlight - Spotlight your business with free links
    BIZZvideos - Videos about businesses, products and business people.
    BIZZbites - "Digg" for Business - Submit your articles and posts

    Know More Media - Health Care / Pharmaceutical / Fitness

    know more media network

    View Network Map

    Network Feed List (OPML)

    Know More Media Network
    Feed


    we support unitus

    PRWeb

    Influencer



    PharmaGazette is a member of the Know More Media network of business related blogs.

    Here are some current headlines from some of our business publications:

    ProductivityGoal

    CallCenterScript

    AdHurl

    TheBizofKnowledge

    LandingTheDeal

    CustomersAreAlways

    HealthCareVox

    BrainBasedBusiness

    TheInsurancePolicy

    MarketingBlurb